PMID- 34689640
OWN - NLM
STAT- MEDLINE
DCOM- 20230216
LR  - 20230224
IS  - 1477-111X (Electronic)
IS  - 0267-6591 (Linking)
VI  - 38
IP  - 2
DP  - 2023 Mar
TI  - Short-term effects of levosimendan use for venoarterial extracorporeal membrane 
      oxygenation: A systematic review and meta-analysis.
PG  - 305-312
LID - 10.1177/02676591211051860 [doi]
AB  - OBJECTIVE: Levosimendan has been demonstrated to reduce the incidence of 
      cardiogenic shock and facilitate weaning from cardiopulmonary bypass. However, 
      the beneficial effects of levosimendan treatment on hospital outcomes in patients 
      receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO) are 
      uncertain. We performed a systematic review and meta-analysis to evaluate the 
      short-term effects of levosimendan use for patients undergoing VA-ECMO. METHODS: 
      We searched PubMed, Embase, and the Cochrane Library for English articles 
      published from inception to July 15, 2021. Observational studies comparing 
      levosimendan versus non- levosimendan for VA-ECMO were considered eligible for 
      the current study. RESULTS: Nine observational studies with 1058 patients were 
      included. In-hospital mortality was 46.3% in the levosimendan group as compared 
      with 50.7% in the control group. Levosimendan significantly reduced in-hospital 
      mortality in patients undergoing VA-ECMO compared with the control group (RR, 
      0.80; 95% CI, 0.67-0.95; p = 0.013). The incidence of weaning from VA-ECMO was 
      79.3% in the levosimendan group as compared with 63.4% in the control group. 
      Levosimendan significantly increase the incidence of weaning from VA-ECMO in 
      patients as compared with the control group (RR, 1.20; 95% CI, 1.07-1.34; p = 
      0.002). In the one-way sensitivity analysis for estimating the effect of each 
      study on mortality or weaning from VA-ECMO, omission of each study did not make a 
      significant difference. CONCLUSIONS: Our study indicates that levosimendan use 
      significantly reduced in-hospital mortality and increase the incidence of weaning 
      in patients undergoing VA-ECMO.
FAU - Yang, Boyu
AU  - Yang B
AD  - The 4th Department of Cardiology, The Sceond Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Zhao, Tong
AU  - Zhao T
AD  - Department of Neurology, Second Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Guo, Bingyan
AU  - Guo B
AD  - The 4th Department of Cardiology, The Sceond Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Li, Yongjun
AU  - Li Y
AUID- ORCID: 0000-0002-3338-5467
AD  - The 4th Department of Cardiology, The Sceond Hospital of Hebei Medical 
      University, Shijiazhuang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20211023
PL  - England
TA  - Perfusion
JT  - Perfusion
JID - 8700166
RN  - 349552KRHK (Simendan)
SB  - IM
MH  - Humans
MH  - Simendan/therapeutic use
MH  - *Extracorporeal Membrane Oxygenation/adverse effects
MH  - Shock, Cardiogenic/drug therapy
MH  - Hospital Mortality
MH  - Intra-Aortic Balloon Pumping
MH  - Retrospective Studies
OTO - NOTNLM
OT  - cardiogenic shock
OT  - levosimendan
OT  - mortality
OT  - venoarterial extracorporeal membrane oxygenation
OT  - weaning
EDAT- 2021/10/26 06:00
MHDA- 2023/02/17 06:00
CRDT- 2021/10/25 05:32
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2023/02/17 06:00 [medline]
PHST- 2021/10/25 05:32 [entrez]
AID - 10.1177/02676591211051860 [doi]
PST - ppublish
SO  - Perfusion. 2023 Mar;38(2):305-312. doi: 10.1177/02676591211051860. Epub 2021 Oct 
      23.